Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Improved Prognostic Performance Model for MRCC

IMDC compared with MSKCC model for renal cell carcinoma

Publish date:: March 24, 2015

The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model has an improved prognostic performance compared with the 3-factor Memorial Sloan Kettering Cancer Center (MSKCC) model and is applicable to a more contemporary cohort in a second-line targeted therapy setting, according to a population-based analysis of 1,021 patients with metastatic renal cell carcinoma who were treated with second-line targeted therapy.

Researchers found 5 out of 6 predefined factors in the IMDC were independent predictors of poor overall survival, including:

• Anemia

• Thrombocytosis

• Neutrophilia

• Karnofsky performance status (KPS) <80

• Less than one year from diagnosis to first-line therapy

The study authors note the IMDC prognostic model can be applied to patients previously treated with targeted therapy, in addition to previously validated populations in first-line targeted therapy.

Citation: Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015;16(3):293-300. doi: 10.1016/S1470-2045(14)71222-7.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,